Hormonal
GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide) reduce major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and cardiovascular mortality in patients with type 2 diabetes and established cardiovascular disease, as well as in non-diabetic patients with obesity and cardiovascular disease.
If you have Type 2 Diabetes and heart disease, or obesity and heart disease, GLP-1 agonists like semaglutide or liraglutide are proven to significantly lower your risk of heart attack, stroke, and heart-related death. This benefit exists alongside blood sugar control. Discuss with your doctor if you are a candidate, considering the cost and injection/oral delivery options.
GLP-1 agonists achieved substantial reductions in myocardial infarction, stroke, cardiovascular mortality, and heart failure events according to major cardiovascular outcome trials (CVOTs). Recent research, notably the pivotal SELECT trial, has confirmed their suitability for non-diabetic subjects with obesity and established CVD.
Why this rating
Based on multiple large-scale Cardiovascular Outcome Trials (CVOTs) with statistically significant hazard ratios.
Source
GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Han‐Mo Yang · Journal of Clinical Medicine · 2025
DOI 10.3390/jcm14196758
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →